DUBLIN–(BUSINESS WIRE)–The “Alzheimer’s Drugs Market Report by Drug Class, Drug Type, Distribution Channel, Region and Company Analysis 2024-2032” report has been added to ResearchAndMarkets.com’s offering.
The global Alzheimer’s drug market reached US$ 6.95 Billion in 2023 and is expected to reach US$ 15.08 Billion through 2032, with a CAGR of 8.99 percent from 2024 to 2032.
Alzheimer’s disease is a situation that causes a sluggish deterioration in memory loss, cognitive capabilities, and the inability to execute each day’s activity. There is presently no cure for Alzheimer’s disease; however, there are drugs that may help control its symptoms and reduce its progression through the years.
Cholinesterase inhibitors, along with donepezil, rivastigmine, and galantamine, are the most commonly used drugs for Alzheimer’s disease. These medicinal drugs improve acetylcholine levels, a neurotransmitter reduced in Alzheimer’s sufferers’ brains. Cholinesterase inhibitors can help specific people enhance their cognitive function, memory, and behavior by increasing their acetylcholine levels.
According to the World Health Organization, more than fifty-five million people worldwide have dementia, with Alzheimer’s disease being the most common. The anticipated growth price for this number is nearly 100% over 2 decades, culminating in a population of 82 million by 2030 and 152 million by 2050.
Number of Alzheimer’s Disease Worldwide
Alzheimer’s disease affects 7 million Americans, with the quantity predicted to rise to 13 million by 2050, consistent with the Alzheimer’s Association.
China Alzheimer’s Drugs Market
China is confronting a rising difficulty with its elderly population, which has resulted in a considerable increase in the incidence of neurological diseases such as Alzheimer’s and other forms of dementia. Alzheimer’s disease remains the most common cause of death in China, ranking fifth on the list of prevalent causes. As a result, it has posed a significant financial strain on individuals, households, and society. In China, more than 15 million people aged 60 and more have dementia, with Alzheimer’s disease accounting for 62% of cases. Alzheimer’s disease grows in prevalence with age, affecting 2-5% of those 65 and older and 15-20% of those 80 and older.
The financial burden is substantial, spending billions of yuan annually and straining healthcare resources. China’s ‘Healthy China Action’ strategy intends to move the focus away from disease treatment and toward health maintenance for the expanding ADRD population. In China, healthcare reimbursement is mainly administered by the NHSA, which covers more than 95% of the population. Reimbursement rates vary depending on insurance plans and medical treatments received, which are classified according to necessity and importance.
In January 2024, Eisai and Biogen disclosed that their Alzheimer’s medication, Leqembi, had been approved in China, making it the third nation to do so after the United States and Japan.
Alzheimer’s Drugs Market Company Overview
Industry leaders in the Alzheimer’s drug market include AbbVie, AstraZeneca, Biogen, Eisai, Eli Lilly, Lundbeck, Roche, Merck, Novartis, Ono Pharmaceutical, Pfizer, and Teva.
Alzheimer’s Drugs Market News
Key Attributes:
Report Attribute | Details |
No. of Pages | 225 |
Forecast Period | 2023 – 2032 |
Estimated Market Value (USD) in 2023 | $6.95 Billion |
Forecasted Market Value (USD) by 2032 | $15.08 Billion |
Compound Annual Growth Rate | 8.9% |
Regions Covered | Global |
Company Analysis: Overview, Recent Developments, Product Portfolio, Financial Insights
Drug Class – Market breakup in 4 viewpoints:
Drug Type – Market breakup in 5 viewpoints:
Distribution Channel – Market breakup in 3 viewpoints:
Country – Market of 25 Countries Covered:
For more information about this report visit https://www.researchandmarkets.com/r/oddmud
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Special Working Group Committed to Strengthening Chinese Investment in Preah Sihanouk Province HONG KONG SAR…
HONG KONG SAR - Media OutReach Newswire - 1 November 2024 - On the evening…
HONG KONG SAR - Media OutReach Newswire - 1 November 2024 - Paul Chan, Financial…
Enticing promotions to thank customers for their support HONG KONG SAR - Media OutReach Newswire…
HO CHI MINH CITY, VIETNAM – Media OutReach Newswire – 1 November 2024 - Ho…
HONG KONG SAR – Media OutReach Newswire - 1 November 2024 – Lionrock Property is…